5

10

15

20

<u>Claims</u>

- 1. Use of PDE4 for identifying a compound which inhibits atherosclerosis or restenosis. 2. The use of claim 1, wherein the PDE4 is PDE4D. 3. The use of claim 2 wherein the PDE4D is PDE4D5 or PDE4D7. 4. The use of claim 2 wherein the PDE4D is PDE4D7. 5. The use of any of claims 1 to 4, wherein said compound inhibits Peripheral Arterial Occlusive Disease. 6. A process for identifying and obtaining a compound for therapy of atherosclerosis or restenosis, said process comprising measuring the activation or inhibition of the phosphodiesterase activity of PDE4. 7. The process of claim 6, wherein said PDE4 is PDE4D. 8. The process of claim 7 wherein the PDE4D is PDE4D5 or PDE4D7. 9. The process of claim 7 wherein the PDE4D is PDE4D7.
- 10. The process of any one of claims 6 to 9, wherein a compound is obtained for the treatment of Peripheral Arterial Occlusive Disease.

5

- 11. A process for identifying and obtaining a compound for therapy of atherosclerosis, or restenosis, said process comprising administering a compound suspected to be an activator or inhibitor of PDE4 to an animal in which atherosclerosis or restenosis is induced, and measuring the extent of atherosclerosis or restenosis as compared to control-treated animals.
- 12. The process of claim 11, wherein said PDE4 is PDE4D.
- 13. The process of claim 12 wherein the PDE4D is PDE4D5 or PDE4D7.
 - 14. The process of claim 12 wherein the PDE4D is PDE4D7.
- 15. The process of any one of claims 11 to 14, wherein the compound is for the therapy of Peripheral Arterial Occlusive Disease.
 - 16. A compound identified by the process of any one of claims 6 to 15.
- 17. A pharmaceutical composition comprising a compound of claim 16 and a pharmaceutically acceptable carrier.
 - 18. Use of a compound of claim 16 for the preparation of a medicament for the treatment of atherosclerosis, restenosis.
- 19. The use of claim 18, wherein said compound is used for the preparation of a medicament for the treatment of Peripheral Arterial Occlusive Disease.

WO 2004/090157 PCT/EP2004/003739

20. The compounds, processes, uses and composition substantially as hereinbefore described, especially with reference to the foregoing examples.